GILEAD VISTIDE FOR CMV RETINITIS LAUNCHED AT $589 PER DOSE; PHASE IV COMMITMENTS INCLUDE LONG-TERM SAFETY FOLLOW-UP OF ALL TREATED PATIENTS
Executive Summary
Gilead's Vistide (cidofovir) was shipped to wholesalers and specialty distributors within hours of its June 26 approval for cytomegalovirus retinitis, the company reported June 27.